A Milestone in Hereditary Cancer Risk Assessment – Major Guidelines Updated

The US-NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines, recognized worldwide as a standard in cancer diagnosis and treatment, have been expanded as knowledge and understanding of hereditary cancer risk grow rapidly.

In particular, the new guidelines for breast, ovarian, pancreatic and prostate cancers include detailed assessments aimed at identifying hereditary risk early. This expansion is intended to broaden hereditary risk assessment alongside NCCN's recently published Genetic/Familial High-Risk Assessment Guidelines for Colorectal, Endometrial and Gastric Cancers as a combined framework.

NOTE: NCCN (National Comprehensive Cancer Network) is an organization of leading cancer centers in the United States that sets standards for cancer diagnosis and treatment. Founded in 1995, it develops comprehensive clinical practice guidelines based on the latest scientific findings and treatment protocols. NCCN is an important reference worldwide in the fight against cancer and helps translate scientific research rapidly into clinical practice.

The Need for and Importance of Expanding the Guidelines

Effective screening and management of people at hereditary cancer risk are vital for early diagnosis and prevention of progression. NCCN Guidelines aim to provide better care for patients and families through evidence-based, scientifically supported recommendations. Continually updated by more than 1,900 experts from 33 NCCN member institutions, these guidelines are among the most comprehensive resources guiding healthcare professionals in cancer care.

Dr. Samir Gupta of the University of California San Diego Moores Cancer Center highlights the importance of expanding the guidelines: “The genetic/familial high-risk assessment guidelines for colorectal, endometrial and gastric cancers were developed based on the latest research and contributions from more than 30 experts. This update includes new criteria for hereditary cancer screening, as well as new recommendations for assessing endometrial and gastric cancer risk,” he explains.

Summary of the New Guidelines: Increasing Use of Genetic Testing

The expanded guidelines were updated as genetic testing becomes more widely used in cancer prevention, screening and treatment. They provide comprehensive information on when testing should be performed, which tests may be more effective and which genetic mutations may be associated with increased cancer risk. They also detail follow-up measures and possible interventions for individuals carrying high-risk genetic mutations.

Dr. Mary B. Daly of Fox Chase Cancer Center says: “NCCN plays an important role in providing the best genetics-based care by establishing guideline panels dedicated to the genetic foundations of major cancers and developing scientifically supported guidelines,” summarizing their contribution to genetic counseling and risk assessment. Dr. Daly also notes that the updates cover the spectrum of genes associated with genetic syndromes, the risk level of each pathogenic variant, advances in screening and prevention strategies, and the use of genetic data in cancer treatment.

Details on Genetic Testing and Specific Genes

• Hereditary genetic testing in prostate cancer should examine multiple genes: BRCA1, BRCA2, ATM, PALB2, CHEK2, HOXB13, MLH1, MSH2, MSH6, PMS2.
• Individuals carrying CDH1 gene mutations should also be referred to specialist centers for the management of gastric cancer risk.

New Recommendations for Endometrial and Gastric Cancers

• Hereditary screening should be recommended for all patients with newly diagnosed endometrial cancer,
• and gastric cancer risk should be managed more carefully in individuals with pathogenic APC variants. For example, upper gastrointestinal endoscopy every 2-3 years if there is also a family history.

The Role of Genetic Counseling and Multigene Testing

• Oncologists should take a family history at initial diagnosis and ask whether the patient has undergone genetic testing for known germline variants.
• Multigene testing should now be preferred over point-mutation tests.

Benefits of the New Guidelines for Patients and Healthcare Professionals

NCCN CEO Dr. Crystal S. Denlinger notes that the expanded guidelines offer expert recommendations based on the latest scientific research across the cancer spectrum: “This information is critical for supporting shared decision-making between healthcare providers and patients, improving screening practices and identifying appropriate prevention or targeted treatment options. Genetic testing guidelines help guide better care for cancer patients and their family members,” she says, emphasizing their importance for healthcare.

Conclusion

Expanding hereditary cancer risk assessment guidelines can be viewed as a revolutionary step in cancer treatment and management. The increasing use of genetic testing allows patients' risks to be defined more clearly. These guidelines help not only patients but also healthcare professionals by improving their knowledge and enabling them to guide treatment in light of scientific advances. By increasing early diagnosis and treatment options for people at hereditary cancer risk, these developments represent a promising approach in the fight against cancer.